Foundayo vs Wegovy pill is now a real choice for adults who want a GLP-1 medicine without a weekly injection. Both are once-daily tablets approved by the FDA for chronic weight management, but they differ in how you take them, how much weight people lost in their trials and what else the label covers. Foundayo (orforglipron) comes from Eli Lilly, while the Wegovy pill is oral semaglutide from Novo Nordisk. Here is what the labels and the published trials show, so you can bring sharper questions to your doctor.
Two Pills Approved Four Months Apart
The Wegovy pill reached the US market first. Novo Nordisk announced on 22 December 2025 that the FDA had approved once-daily oral semaglutide 25 mg for weight reduction and long-term weight maintenance, and said it expected a US launch in early January 2026. Semaglutide is the same active ingredient found in Ozempic and in the Wegovy injection, so doctors already know its effects well. What changed is the delivery: a daily tablet instead of a weekly pen under the skin. If you want the background on how the tablet stacks up against the pen, our earlier piece on the Wegovy pill versus injectables walks through that comparison in detail.
The FDA approved Foundayo on 1 April 2026 for adults with obesity, or adults with overweight and at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. The agency issued the decision 50 days after filing under its Commissioner's National Priority Voucher pilot program and called it the fastest approval of a new molecular entity since 2002. Orforglipron is not a peptide like semaglutide. It is a small molecule that acts on the same GLP-1 receptor, and its label sets no rules on food or water. That chemistry matters less to most patients than the daily routine, the expected results and the side effects, so the Foundayo vs Wegovy pill question really starts there.
How You Take Each Pill Every Day
The biggest practical difference is the morning routine. According to the Wegovy prescribing information, the tablet is taken once a day on an empty stomach in the morning with no more than 4 ounces of water and with no other drink. After swallowing it, the patient waits at least 30 minutes before eating, drinking anything else or taking other oral medicines. The label starts at 1.5 mg for the first 30 days, then steps up to 4 mg and 9 mg before reaching the 25 mg maintenance dose from day 91. These are label amounts for an approved drug, and only a prescriber should decide whether someone starts the pill and how fast they move through the steps.
Foundayo is simpler on paper. The Foundayo prescribing information says to take one tablet once daily with or without food, swallowed whole and never broken, crushed or chewed. There is no water limit and no waiting window, which suits people who take several medicines each morning or who skip breakfast on busy days. The label starts at 0.8 mg and allows a step up only after at least 30 days on each dose, up to a maximum of 17.2 mg once daily. The same label adds a detail that is easy to miss: people using oral hormonal birth control are advised to switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase.
| Foundayo | Wegovy pill | |
|---|---|---|
| Ingredient | Orforglipron, a small molecule | Semaglutide, a peptide |
| Maker | Eli Lilly | Novo Nordisk |
| FDA approval | 1 April 2026 | 22 December 2025 |
| How to take it | Once daily, with or without food | Once daily on an empty stomach, up to 4 oz of water, then a 30 minute wait |
| Label starting and top dose | 0.8 mg and 17.2 mg | 1.5 mg and 25 mg |
| Main trial result | 11.2% vs 2.1% placebo at 72 weeks (ATTAIN-1, highest dose) | 13.6% vs 2.2% placebo at 64 weeks (OASIS 4) |
| Heart risk indication | No | Yes, in adults with established heart disease |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
What the Weight Loss Trials Found
Foundayo's main evidence is the ATTAIN-1 trial, published in the New England Journal of Medicine. It enrolled 3,127 adults with obesity but without diabetes and followed them for 72 weeks on top of advice on healthy eating and physical activity. Average body weight fell by 7.5%, 8.4% and 11.2% across the three doses tested, compared with 2.1% on placebo. Those figures come from the treatment-regimen estimand, which counts everyone who was randomized, including people who stopped taking the drug. Headlines sometimes quote higher numbers that only count people who stayed on treatment, so it is worth checking which kind of figure an article or an advert is using before comparing one drug with another.
The Wegovy pill was tested in OASIS 4, also reported in the same journal. That smaller trial randomized 307 adults with obesity, or overweight plus a weight-related complication, and no diabetes, two to one to oral semaglutide 25 mg or placebo. At 64 weeks, average weight change was minus 13.6% with the pill against minus 2.2% with placebo, and Novo Nordisk reports a mean loss of 16.6% among people who stayed on treatment. The two trials differ in size, length, dose steps and population, so they cannot be read as a head-to-head contest. We found no published trial that compares the two pills directly, so any Foundayo vs Wegovy pill ranking based on these numbers is an estimate.
Side Effects Warnings and Switching From Injections
Both pills belong to the GLP-1 class and share its typical problems. On the Foundayo label, the most common side effects, seen in at least 5% of patients, are nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, bloating, fatigue, burping, reflux, gas and hair loss. The Wegovy label lists a similar gastrointestinal pattern. Both carry a boxed warning about thyroid C-cell tumors seen in rodents, and neither should be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Neither label recommends combining the pill with another GLP-1 medicine. If you want the patient view, read what users said about the side effects no one mentioned in their own words.
For people already on injections, the two labels and the newest data point in different directions. The Wegovy label lets patients on the 2.4 mg weekly injection start the 25 mg tablet one week after their last shot, and the tablet is also indicated to cut the risk of heart attack, stroke and cardiovascular death in adults with established heart disease and obesity or overweight. Foundayo has no heart indication. Its case for keeping weight off rests on ATTAIN-MAINTAIN, published in Nature Medicine in May 2026: people who switched from tirzepatide or semaglutide injections kept about 75% and 79% of their earlier weight loss at one year, against 49% and 38% on placebo. Our guide to switching from injectable to oral GLP-1s covers the practical side.
Conclusion
The Foundayo vs Wegovy pill choice comes down to routine, evidence and health goals rather than a clear winner. Foundayo fits more easily into a busy morning because food and water timing do not matter, while the Wegovy pill showed the larger weight change in its own trial and carries a heart risk indication. Both need a prescription, a slow dose climb and an honest talk about side effects and cost. Stopping either one tends to bring weight back, as our piece on stopping weight loss medication explains, so plan for the long term.
This article is for general information only and is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any weight loss medicine, and read our health disclaimer.
Sources
- US Food and Drug Administration, press announcement on the Foundayo approval, 1 April 2026
- Foundayo (orforglipron) tablets, prescribing information, DailyMed
- Wegovy (semaglutide) injection and tablets, prescribing information, DailyMed
- Novo Nordisk press release on the Wegovy pill approval, 22 December 2025
- ATTAIN-1, N Engl J Med 2025;393:1796-1806, PMID 40960239
- OASIS 4, N Engl J Med 2025;393:1077-1087, PMID 40934115
- ATTAIN-MAINTAIN, Nature Medicine 2026, doi 10.1038/s41591-026-04386-7, PMID 42120723
